数据
资源
版本对比
免费注册
预约演示
免费注册
World First Use of
Lightpoint
's SENSEI® Drop-In Gamma Probe in
Bladder Cancer
Surgery Performed in Spain
2024-03-26
·
BioSpace
放射疗法
LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Lightpoint Surgical Limited (
Lightpoint
), an affiliate of
Telix Pharmaceuticals Limited
(ASX: TLX,
Telix
, the Company) today announces a world-first
bladder cancer
sentinel lymph node (SLN) procedure with SENSEI®,
Telix
's miniature robotic-assisted gamma probe used to detect radiation in patients and guide surgery. The patient was operated on at
Hospital del Mar
in Barcelona, Spain. SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery. The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder. With broad application in radio-guided surgery across multiple procedures and major
cancer
types, SENSEI® is currently indicated for use during SLN biopsy in
prostate, endometrial and cervical cancers
. As part of an investigator-initiated clinical trial, SENSEI® was used by Dr. Lluís Cecchini with the da Vinci Xi surgical robotic platform in a patient scheduled for radical cystectomy and Bricker urinary diversion with SLN biopsy. Dr. Lluís Cecchini, Head of Urology at
Hospital del Mar
said, "Lymph nodes around the bladder have a high chance of being cancerous and are therefore important to excise. Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery. The size and flexibility of SENSEI® meant it was easy to manipulate within the surgical cavity, see the gamma signal within the robotic console, and quickly locate the SLN, where I might otherwise not have known it was present. Being able to perform the procedure with minimal impact on surrounding healthy tissue is a high surgical priority. With SENSEI® we can deliver a more targeted, focused, and less complex experience for patients." Nynke van den Berg, General Manager Medical Technologies (
MedTech
) at
Telix
added, “A first
bladder cancer
procedure with the SENSEI® drop-in gamma probe is a significant milestone for
Telix
and the
Lightpoint
team. As we focus on aligning SENSEI® with our
Illuccix
® and
TLX599-CDx
programs for
prostate cancer
, this successful procedure demonstrates the potential and scope to expand use into other
urologic malignancies
– in line with our portfolio approach to support the patient from diagnosis to surgical intervention and therapy.” About SENSEI®
Lightpoint
has developed SENSEI® - a miniaturised surgical gamma probe for minimally invasive and robot-assisted surgery. The device is approved for sale in the US, EU, UK, and Australia and is in clinical use in the US, UK, Germany, France, Netherlands, Belgium, and Spain. About
Lightpoint
Lightpoint Surgical Ltd (
Lightpoint
) is an affiliate of
Telix Pharmaceuticals Limited
. As the
MedTech
division of
Telix
,
Lightpoint
is focused on the development of precision-guided surgical solutions and complementary Artificial Intelligence technologies to aid detection, management and treatment of
cancer
and rare diseases.
Lightpoint
is headquartered in the United Kingdom.
Telix
Investor Relations Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com Legal Notices The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of
Telix Pharmaceuticals Limited
(
Telix
) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification. This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of
Telix
’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of
Telix
’s preclinical and clinical studies, and
Telix
’s research and development programs;
Telix
’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of
Telix
’s product candidates, if or when they have been approved; estimates of
Telix
’s expenses, future revenues and capital requirements;
Telix
’s financial performance; developments relating to
Telix
’s competitors and industry; and the pricing and reimbursement of
Telix
’s product candidates, if and after they have been approved.
Telix
’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website. To the maximum extent permitted by law,
Telix
disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions. ©2024
Telix Pharmaceuticals Limited
. The
Telix Pharmaceuticals
,
Lightpoint
,
Illuccix
® and SENSEI® names and logos are trademarks of
Telix Pharmaceuticals Limited
and its affiliates – all rights reserved.
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Lightpoint Corp.
Telix Pharmaceuticals Ltd.
Telix d.o.o.
[+2]
适应症
膀胱癌
肿瘤
前列腺癌
[+1]
靶点
-
药物
Gallium GA-68 Gozetotide
TLX-599-CDx
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
2024年4月全球首批及特殊审评药物报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务